Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells(First Affiliated Hospital of Zhejiang University)

This is a single-arm, open-label, dose escalation, phase I study, aiming to evaluate the safety and efficacy of Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific Chimeric Antigen Receptor (CAR) T-cells in patient with relapsed or refractory diffuse B cell lymphoma.